Skip to main content
Equibles

LOS ANGELES CAPITAL MANAGEMENT LLC

Position in RPRX — Royalty Pharma plc

CIK 1177206 LOS ANGELES, CA
Back to RPRX Full portfolio

Position in RPRX

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$49,211,181
+$2,587,843 QoQ
Shares Held
877,674
-9.7% QoQ
Ownership
0.153%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#62
of 646 holders
Holding Since
Dec 2020
23 quarters on record
Voting authority Sole 58% Shared 0% None 42%

Common Shares in RPRX Over Time

Shares Held

Position Value (USD)

Position in Biotechnology

Healthcare · as of Jun 30, 2026

LOS ANGELES CAPITAL MANAGEMENT LLC holds $888,466,927 across 167 Biotechnology names. RPRX ranks #8 (5.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 ALNY
Alnylam Pharmaceuticals, Inc.
 729,635 $219,642,024
2 HALO
Halozyme Therapeutics, Inc.
 1,938,035 $151,689,999
3 CAI
Caris Life Sciences, Inc.
 3,958,531 $70,541,022
4 INCY
Incyte Corp
 578,986 $65,633,852
5 VRTX
Vertex Pharmaceuticals Inc / Ma
 130,802 $64,973,277
6 EXEL
Exelixis, Inc.
 1,159,457 $63,086,055
7 REGN
Regeneron Pharmaceuticals, Inc.
 98,585 $61,471,690
8 RPRX
Royalty Pharma plc
This page 		877,674 $49,211,181

All Filings in RPRX

Export CSV
23 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $49,211,181 877,674
2026-03-31 $46,623,338 971,927
2025-12-31 $47,489,951 1,229,036
2025-09-30 $35,870,657 1,016,742
2025-06-30 $11,412,538 316,751
2025-03-31 $33,655,514 1,081,128
2024-12-31 $1,043,205 40,894
2024-09-30 $10,967,948 387,697
2024-06-30 $11,749,100 445,548
2024-03-31 $21,378,020 703,919
2023-12-31 $11,403,725 405,971
2023-09-30 $11,712,158 431,546
2023-06-30 $9,386,950 305,366
2023-03-31 $19,698,826 546,734
2022-12-31 $10,524,136 266,299
2022-09-30 $6,757,191 168,173
2022-06-30 $10,647,302 253,266
2022-03-31 $11,469,785 294,399
2021-12-31 $7,265,890 182,331
2021-09-30 $12,322,981 340,979
2021-06-30 $39,760,545 970,006
2021-03-31 $38,810,938 889,751
2020-12-31 $13,070,307 261,145